Clinical Trials in Fuyang, China
5 recruiting
Showing 1–12 of 12 trials
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled399 locationsNCT06531824
Recruiting
Not Applicable
The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases
Cardiovascular Diseases
AstraZeneca3,000 enrolled69 locationsNCT06909773
Recruiting
Not Applicable
Hyperkalemia Quality Improvement Program (HK-QIP) Study
Hyperkalemia
AstraZeneca1,000 enrolled49 locationsNCT06884267
Recruiting
Phase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled753 locationsNCT06742723
Recruiting
Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626
Recruiting
Not Applicable
The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents
CPTSD, Compelx Post-traumatic Stress Disorder
Peking University120 enrolled2 locationsNCT07325734
Recruiting
China Liver Cancer Clinical Registry Cohort Database (HEAL)
Liver Cancer
Anhui Provincial Hospital10,000 enrolled38 locationsNCT06777485
Recruiting
Phase 4
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
HypertensionMTHFR 677 CC or CT GenotypeElevated Plasma Homocysteine (Hcy≥10µmol/L)+1 more
Shenzhen Ausa Pharmed Co.,Ltd32,000 enrolled20 locationsNCT04974138
Recruiting
Phase 4
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
HypertensionMTHFR 677 TT Genotype
Shenzhen Ausa Pharmed Co.,Ltd24,000 enrolled20 locationsNCT04974151
Recruiting
Phase 2
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
Anhui Provincial Hospital60 enrolled2 locationsNCT06664021
Recruiting
Phase 2
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
Hepatocellular Carcinoma
Anhui Provincial Hospital45 enrolled2 locationsNCT06498622
Recruiting
Not Applicable
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
Metastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the LiverMulti-organ Metastatic Colorectal Cancer
Anhui Provincial Hospital130 enrolled6 locationsNCT06449937